Current Report Filing (8-k)
July 10 2019 - 04:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 10, 2019
SUNESIS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-51531
|
|
94-3295878
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
395 Oyster Point Boulevard, Suite 400
South San Francisco, California
|
|
94080
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (650)
266-3500
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol
|
|
Name of each exchange
on which registered
|
Common Stock, $0.0001 par value
|
|
SNSS
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 2.02.
|
Results of Operations and Financial Condition.
|
On a preliminary unaudited basis, Sunesis Pharmaceuticals, Inc. estimates that our cash and cash equivalents as of June 30, 2019 was approximately
$17.7 million. The estimate is a preliminary estimate based on currently available information and does not present all necessary information for a complete understanding of our financial condition as of June 30, 2019 or our results of
operations for the three and six months ended June 30, 2019.
The information in this Item 2.02 is furnished and shall not be deemed
filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in
this Item 2.02 shall not be incorporated by reference into any filing with the SEC made by Sunesis, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
We are filing our July 2019 investor presentation as Exhibit 99.1 to this Current Report on Form
8-K
which we intend
use from time to time in meetings with stockholders and analysts.
The information contained in the presentation should be considered in the context of
our filings with the Securities and Exchange Commission and other public announcements we may make by press release or otherwise from time to time. Information concerning risk factors affecting our business can be found in our periodic filings with
the Securities and Exchange Commission at www.sec.gov.
The presentation speaks only as of the date of this Current Report on Form
8-K
and we expressly disclaim any obligation to release publicly any updates or any changes in our expectations or any change in events, conditions, or circumstances on which any forward-looking statement in the
presentation is based, except as required by law.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d)
Exhibits
.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
SUNESIS PHARMACEUTICALS, INC.
|
Dated: July 10, 2019
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ William P. Quinn
|
|
|
|
|
|
|
William P. Quinn
|
|
|
|
|
|
|
Chief Financial Officer, Senior Vice President,
Finance and Corporate Development
|
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Mar 2023 to Mar 2024